Clinical trials: Hepatic Neoplasm
Hepatocellular Carcinoma (HCC), MASLD-HCC
Single-Cell Profiling of Liver-infiltrating Immune Cells of Patients with NASH- and Virus-related HCC: Implications for Immunotherapy
The goal of this observational study is to learn about the the immune landscape of HCC arising from different etiology, such as MASLD and viral hepatitis, at single cell level.
- Conditions
- Hepatocellular Carcinoma (HCC), MASLD-HCC, HCV_HCC
- Trial name
- 1003rcr2022_72 (NCT06899763)
- Where
- Italy
- Volunteers
- 6 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Carcinoma, Hepatocellular, Neuroendocrine Tumors
Circulating Tumor Cells and Tumor DNA in HCC and NET
Background Treatment and control of cancer is associated with high costs, to patients in the form of side effects and discomfort during investigations, to society in the form of expensive drugs and studies.
- Trial name
- NCT02973204
- Testing
- Sorafenib, Radiofrequency ablation (RFA) or surgery, Everolimus
- Where
- Denmark
- Volunteers
- 167 people
- Sponsor
- University of Aarhus
Advanced Adult Hepatocellular Carcinoma, Child-Pugh Class A
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
This phase Ib/II trial studies how well sorafenib tosylate and pembrolizumab work in treating patients with liver cancer that has spread to other parts of the body.
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Child-Pugh Class A, Stage III Hepatocellular Carcinoma, Stage IIIA Hepatocellular Carcinoma
- Trial name
- NCT03211416
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Sorafenib Tosylate
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Roswell Park Cancer Institute
Chronic Hepatitis B Virus (HBV) Infection
New HBV Infection Biomarkers: Clinical Characterization and Impact on Management
Chronic Hepatitis B Virus (HBV) infection affects nearly 300 million people worldwide and is a leading cause of liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). In France, it affects around 0.3% of the population.
- Trial name
- HBV-Biomark (NCT06906016)
- Testing
- Collection of blood samples for the study of HBV biomarkers
- Where
- France
- Volunteers
- 900 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma
Hepatocellular Carcinoma Registry for Turkey (3K Trial)
This registry study is national, multi-center, prospective study without any interventions to the treatment strategies and/or decisions of the investigators.
- Trial name
- NCT01473121
- Testing
- No Intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 600 people
- Sponsor
- Bayer
Liver Diseases, Hepatocellular Carcinoma
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
This study intends to evaluate the efficacy and safety of blank- microsphere transcatheter arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin (bTAE-HAIC) plus Lenvatinib and…
- Conditions
- Liver Diseases, Hepatocellular Carcinoma, Immunotherapy, Camrelizumab
- Trial name
- NCT06061276
- Testing
- bTAE-HAIC, Lenvatinib, Camrelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
This research study will evaluate Sorafenib (Nexavar®) and Capecitabine (Xeloda®) to see the following: how effective this combination of study drugs will be in treating HCC how long subjects respond to these study drugs what…
- Trial name
- NCT01032850
- Testing
- Sorafenib & Capecitabine
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- New Mexico Cancer Research Alliance
Hepatocellular Carcinoma
Efficacy of Sirolimus In Liver Transplantation for Hepatocellular Carcinoma (HCC)
The purpose of this study is to evaluate the anti-tumor effect of sirolimus-based immunosuppressive regimen in patients following living donor liver transplantation for hepatocellular carcinoma exceeding Milan criteria with…
- Trial name
- Sirolimus (NCT01374750)
- Testing
- Sirolimus, m-TOR inhibitor free
- Where
- South Korea
- Volunteers
- 45 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous…
- Trial name
- COSMIC-312 (NCT03755791)
- Testing
- Cabozantinib, Sorafenib, Atezolizumab
- Where
- 245 sites in United States, Argentina and 32 more
- Volunteers
- 837 people
- Sponsor
- Exelixis
Hepatocellular Carcinoma
Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer
This phase II trial studies how well perflutren protein-type A microspheres and contrast-enhanced ultrasound work in improving response to radioembolization therapy in patients with liver cancer.
- Trial name
- NCT03199274
- Testing
- Yttrium-90 Microsphere Radioembolization, Perflutren Protein-Type A Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Thomas Jefferson University
Hepatocellular Carcinoma, Hepatoma
A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma
This is a prospective, multicenter study that will be conducted at up to 40 centers in the United States and Outside United States (OUS).
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma
- Trial name
- SOLACE (NCT02460991)
- Testing
- DEB-TACE, Sorafenib
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Boston Scientific Corporation
Primary Hepatocellular Carcinoma
Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
A multicentre, randomized, open-label, parallel-group, active controlled study.
- Trial name
- NCT02956772
- Testing
- TACE, Arsenic trioxide
- Where
- 9 sites in China
- Volunteers
- 190 people
- Sponsor
- Hunan Provincial People's Hospital
Liver Cancer
Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01182272
- Testing
- sorafenib tosylate, laboratory biomarker analysis, neoadjuvant therapy
- Where
- France
- Volunteers
- 36 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Hepatocellular Carcinoma
FLNA in HCC Patients
The risk of recurrence after hepatectomy for hepatocellular carcinoma (HCC) is very high. Having a predictive marker of early recurrence (ER) would be desirable to personalize the follow-up and possibly develop new targeted…
- Trial name
- NCT03081637
- Volunteers
- 115 people
- Sponsor
- University of Milan
Hepatocellular Carcinoma
Establishment of a Tissue Registry for Hepatocellular Carcinoma Specimens
The goal of the study is to establish a cancer registry to facilitate research and assist in the identification of additional risk factors for hepatocellular carcinoma. The main objectives are: 1.
- Trial name
- TIR-HCC (NCT05935189)
- Where
- Armenia
- Volunteers
- 500 people
- Sponsor
- Nikomed Medical Center
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
This randomized phase III trial studies chemoembolization and sorafenib tosylate to see how well they work compared with chemoembolization alone in treating patients with liver cancer that cannot be removed by surgery.
- Trial name
- NCT01004978
- Testing
- Cisplatin, Computed Tomography, Doxorubicin Hydrochloride
- Where
- 281 sites in United States
- Volunteers
- 235 people
- Sponsor
- National Cancer Institute (NCI)
Hepatic Small Vessel Neoplasm
Hepatic Small Vessel Neoplasm
Small-vessel hepatic tumor is a new tumor entity of vascular origin, described in 2016 by Gill et al, in a series of 17 patients.
- Trial name
- IMAHEP (NCT06067035)
- Testing
- Imaging
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma, HCC
Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant
This study will compare stereotactic body radiation therapy (SBRT) to trans-arterial chemoembolization (TACE) as a bridging strategy for patients with HCC undergoing liver transplantation.
- Trial name
- SBRTvsTACE (NCT03960008)
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Trans-Arterial Chemoembolization (TACE), Doxorubin
- Where
- 5 sites in United States, Canada
- Volunteers
- 9 people
- Sponsor
- Lahey Clinic
Liver Cirrhosis, Carcinoma, Hepatocellular
Gadoxetic Acid-enhanced MR Evaluation of Hepatocellular Carcinoma and Dysplastic Nodules in the Cirrhotic Liver
A prospective intra-individual study to investigate the diagnostic performance of gadoxetic acid-enhanced MR for the patients with liver cirrhosis using thin-section whole-explant as standard of reference
- Trial name
- PriMPa (NCT01501240)
- Where
- 2 sites in South Korea
- Sponsor
- Jae Ho Byun
Hepatocellular Carcinoma
Sialic Acid in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) accounts for approximately 90% of the cases of liver cancer and is associated with high morbidity and mortality.
- Trial name
- NCT06836518
- Testing
- serum sialic acid
- Volunteers
- 100 people
- Sponsor
- Sohag University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.